Ovarian carcinoma is the leading cause of death from gynecological cancers in many Western countries. Aberrant glycosylation is an important aspect in malignant transformation and consequently in ovarian cancer. In this study, a detailed structure analysis of the N-linked glycans from total glycoproteins from the SKOV3 ovarian carcinoma cell line and from a recombinantly expressed secretory glycoprotein, erythropoietin (EPO), produced from the same cells has been performed using high-performance anion exchange chromatography with pulsed amperometric detection and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Total cellular N-glycans contained high-mannose type and proximally fucosylated complex type partially agalactosylated structures. On the other hand, the recombinant human EPO secreted from SKOV3 cells contained predominantly core-fucosylated tetraantennary structures, which were partially lacking one or two galactose residues, and partially contained the LacdiNAc motif. Only minor amounts of di-and triantennary complex-type glycans were found, and high-mannose-type glycans were not present in the secreted EPO protein. A large amount of N-acetylneuraminic acid in α2,3-linkage was detected as well. Endogenous glycoproteins were also found to contain the LacdiNAc motif in N-linked glycans. This work contributes to the knowledge of the glycosylation of a human ovarian cancer cell line. It also establishes the basis to further explore high-mannose-type glycans, and the LacdiNAc motif as possible markers of ovarian carcinoma.
Introduction
In cancer, changes in the glycan biosynthetic pathway are common and malignant transformation is normally associated with the under-or overexpression as well as neoexpression of glycan structures that can contain terminal antigenic determinants (Dube and Bertozzi 2005) .
Ovarian carcinoma is the leading cause of death from gynecological cancers in many Western countries. At this point, the chances of survival are drastically decreased. The molecular marker commonly employed to diagnose epithelial ovarian cancer is the serum mucin-like glycoprotein CA125 (Gadducci et al. 2004; Ayhan et al. 2007 ). In addition, aberrant glycosylation also occurs in ovarian carcinoma. For example, Lewis y (Fucα2Galβ4[Fucα3]GlcNAc-R), sialyl-Lewis x (NeuAcα2,3 Galβ4[Fucα3]GlcNAc-R), sialyl-Tn (NeuAcα2,6GalNAcα-Ser/ Thr), and Tn antigens were found in primary ovarian carcinomas and their metastases (Davidson et al. 2000) . Furthermore, mucinous tumors were found to express sialyl-Tn, Lewis a (Galβ3[Fucα4]GlcNAc-R), and sialyl-Lewis a (NeuAcα2, 3Galβ3[Fucα4] GlcNAc-R, CA19-9 marker) strongly and homogeneously, whereas serous and endometrioid tumors strongly expressed Lewis y and H type 2 antigen (Federici et al. 1999) . More recently, complex-type bisecting glycans have also been described in tissues of endometrioid ovarian cancers (Abbott et al. 2008) . Furthermore, higher levels of sialyl-Lewis x were found in serum haptoglobin and α1-antichymotrypsin from patients with ovarian cancer, and the immunoglobulin G (IgG) contained agalactosylated diantennary glycans with increased core fucosylation (Saldova et al. 2007 ). Alterations in fucosylation and branching in α1-acid glycoprotein have also been proposed as potential biomarkers of ovarian cancer (Imre et al. 2008) .
These changes in carbohydrate expression are the result of a deregulation of the glycosylation pathway. In fact, increased expression of several glycosyltransferases involved in the synthesis of these antigens were reported: altered mRNA levels of α2,3-and α2,6-sialyltransferases in the tissues of serous ovarian cancer (Wang et al. 2005) ; elevated expression of N-acetylglucosaminyltransferase V in mucinous ovarian carcinoma tissues (Takahashi et al. 2009 ); elevated α6-fucosyltransferase in serous adenocarcinomas (Takahashi et al. 2000) ; elevated α3/4-fucosyltransferase activities in ovarian cancer (Chandrasekaran et al. 1992) .
The characterization of the glycosylation properties of ovarian cancer cell lines is easier since these cells are easily grown in vitro in large amounts. Glycosylated structures specific to the tumor cell lines may constitute potential biomarkers to be further explored in the pathology of the disease. At present, there are only few studies describing glycosylation properties of ovarian carcinoma cells. Previously, CA125 from the OVCAR-3 cell line showed predominantly high-mannose and complex bisecting-type N-linked glycans (Kui Wong et al. 2003) . On the other hand, in our previous work, several ovarian carcinoma cell lines, SKOV3, GG, OVM, and m130, were characterized with respect to their glycosylation using anticarbohydrate antibodies and lectins (Escrevente et al. 2006 ). The cells contained variable amounts of Lewis carbohydrate motifs and all contained glycoproteins recognized by Concanavalin A (ConA), a lectin that binds high-mannose and hybrid-type glycans, and Sambucus nigra (SNA) lectin that binds structures containing terminal α2,6-linked sialic acid. More recently, a new monoclonal antibody against high-mannose-type structures was found to recognize several tumor cells including ovarian cancer cell lines (Newsom-Davis et al. 2009 ).
In the present work, we have characterized in detail the N-glycosylation from the total cellular glycoproteins from the SKOV3 ovarian carcinoma cell line and from a secretory recombinant human glycoprotein, erythropoietin (EPO), produced from these cells. High-performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI/TOF-MS) analysis showed that total glycoproteins contained high-mannose-type glycans, whereas the secreted glycoprotein recombinantly expressed from the same cells contained, predominantly, corefucosylated partially agalactosylated tetraantennary complex glycans. In addition, evidence is provided indicating the presence of the terminal motif GalNAcβ4GlcNAc (LacdiNAc) in the recombinant human EPO as well as in endogenous glycoproteins from SKOV3 cells.
Results

Structural analysis of SKOV3 desialylated N-glycans
The N-glycans from total tryptic glycopeptides of SKOV3 ovarian carcinoma cells were characterized after their release with peptide-N-glycosidase F (PNGase F). After desalting, N-glycans were desialylated by mild acid hydrolysis and were analyzed by HPAEC-PAD mapping ( Figure 1C) . A peak corresponding to N-acetylneuraminic acid (NeuAc) indicated the presence of peripheral NeuAc in SKOV3 cell glycoproteins. Complex-type N-glycans were detected at retention times between 18 and 30 min ( Figure 1B ), peak g comigrating with a tetraantennary complex structure with proximal Fuc Fig. 1 . HPAEC-PAD analysis of the desialylated N-glycans released from SKOV3 cells and EPO SKOV3 . (A) High-mannose-type glycan standards from RNase B, structures are: M5, Man 5 GlcNAc 2 ; M6, Man 6 GlcNAc 2 ; M7, Man 7 GlcNAc 2 ; M8, Man 8 GlcNAc 2 ; M9, Man 9 GlcNAc 2 . (B) Complex-type reference glycan standards from EPO from CHO cells, structures (all proximally α6-fucosylated) are: A, diantennary; B, 2,4-triantennary; C, 2,6-triantennary; D, tetraantennary; E, triantennary + one LacNAc repeat; F, tetraantennary + one LacNAc repeat; G, triantennary + two LacNAc repeats; H, tetraantennary + two LacNAc repeats; I, triantennary + three LacNAc repeats and tetraantennary + three LacNAc repeats. (C) Total N-glycans of SKOV3 cells (mock-transfected). (D) Total N-glycans of EPO SKOV3 . Fractions a-h and w-z were subjected to MALDI/TOF-MS analysis. Asterisks indicate high-mannose-type glycans with 5-9 mannose residues assigned based on retention time and MALDI/TOF-MS analysis of the corresponding fractions collected after on-line desalting.
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( Figure 1C ). The majority of the peaks, which were assigned with an asterisk, had retention times identical to high-mannose-type glycans, and consisted predominantly of Man 5 GlcNAc 2 , Man 6 GlcNAc 2 , Man 7 GlcNAc 2 , Man 8 GlcNAc 2 , and Man 9 GlcNAc 2 ( Figure 1A and C).
The total pool of N-glycans from SKOV3 cells was also analyzed by MALDI/TOF-MS (Figure 2A) . Furthermore, the individual fractions a-h from the HPAEC-PAD profiles ( Figure 1C ) were collected after on-line desalting and were analyzed by MALDI/TOF-MS (data not shown). The results of the detected m/z signals, proposed composition, and proposed structures are shown in Table I .
The highest intensity mass signals were found at m/z 1257. 4, 1419.5, 1581.5, 1743.6, and 1905.6 (Figure 2A , Table I ) and corresponded to the high-mannose-type structures Man 5 GlcNAc 2, Man 6 GlcNAc 2 , Man 7 GlcNAc 2 , Man 8 GlcNAc 2 , and Man 9 GlcNAc 2 , respectively.
In addition to the high-mannose-type structures, complextype glycans were detected. Mass signals at m/z 1809.6 and 2174.8 ( Figure 2A , Table I ) together with the retention times in HPAEC-PAD analysis indicated that these peaks corresponded to diantennary and triantennary complex-type glycans with proximal Fuc, respectively. Peripheral fucose could be excluded since Lewis a has not been found in SKOV3 cells whereas Lewis x was only found at very low levels in few cells (Escrevente et al. 2006 ). Signals at m/z 1850.7 and 2012.7 probably corresponded to truncated triantennary complex-type glycans − one or two Gal residues, respectively. Signals at m/z 2377.8 and 2742.9 are proposed to correspond to complex-type tetraantennary and tetraantennary with one N-acetyllactosamine (LacNAc) repeat and proximal Fuc, minus one Gal residue, respectively ( Figure 2A , Table I ).
Proteins from SKOV3 cell extracts and supernatants produced in the absence of serum have also been detected on blot with the lectin from Wisteria floribunda (WFA) that is known to bind the LacdiNAc motif (Sato et al. 1993 ; Figure 3 ). As control, the incubations were performed in the presence of 0.2 M GalNAc. In the supernatant, several proteins were detected, most relevant a strong band at an apparent molecular mass of 110 kDa was specifically recognized by WFA, which indicated the presence of the LacdiNAc motif. This band disappeared after incubation with PNGase F showing that the LacdiNAc motif was present in N-linked glycans. Between 60 and 30 kDa, there was a set of bands that were also detected with the lectin; however, some were probably due to nonspecific binding since they were still detected in the presence of GalNAc. The cellular extracts showed a band at molecular mass between 160 and 110 kDa that contained the LacdiNAc motif and was present in N-glycans.
Therefore, glycoproteins from SKOV3 cells were found to contain high-mannose structures, core-fucosylated complextype structures partially agalactosylated, and the LacdiNAc motif.
Production and deglycosylation of EPO SKOV3
Since the detection of large amounts of high-mannose structures in the total cellular N-glycans was unexpected, we have probed the cellular glycosylation machinery of SKOV3 cells by transfecting the cells with a vector encoding human EPO whose glycosylation has been well characterized. Biological reference prepared (EPO BRP ) is produced by Chinese hamster ovary (CHO) host cells, and the N-glycans consist of corefucosylated tetraantennary complex-type structures with or without one, two or three LacNAc repeats and with α2,3-NeuAc (Sasaki et al. 1987; Takeuchi et al. 1988; Takeuchi and Kobata 1991; Brito et al. 2008) .
Stably transfected SKOV3 cells were used for EPO production from confluent monolayers in the absence of serum. The cells did not secrete endogenous EPO (data not shown). The amount of produced protein was estimated at 40 µg/L. This low amount is not expected to saturate the glycosylation machinery of the cells and, therefore, should not affect their normal glycosylation. EPO SKOV3 was purified by immunoaffinity chromatography and had 35 kDa by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which was slightly lower than the estimated mass of 39 kDa for EPO BRP ( Figure 4A ).
EPO SKOV3 was resistant to endoglycosidase H (Endo H) (cleaves the β4-linkage between the two GlcNAc residues of the chitobiose core of high-mannose and hybrid-type structures) but digestion with PNGase F (cleaves between the innermost GlcNAc and the Asn residue of high-mannose as well as complex-type N-glycans) yielded two bands ( Figure 4A ), which indicated the absence of high-mannose and the presence of complex glycans. The lower band at 18 kDa consisted of the polypeptide chain (calculated mass 18,398 Da; Lai et al. 1986) , and the upper band ( Figure 4A , closed arrowhead) probably corresponded to an O-glycosylated glycoform, as observed before for other recombinant EPO (Tsuda et al. 1990; Schlenke et al. 1999 ). In addition, EPO SKOV3 and EPO BRP incubated with neuraminidases from Vibrio cholerae (cleaves NeuAc in the α2,3-, α2,6-, or α2,8-linkages) and Streptococcus pneumoniae (cleaves NeuAc in the α2,3-linkage) showed similar downward shifts, which indicated the presence of α2,3-linkage ( Figure 4A ). This result was further confirmed by the detection of EPO SKOV3 with the lectin from Maackia amurensis (MAL; binds terminal NeuAcα2,3Gal), but not with the lectin from SNA (binds terminal NeuAcα2,6Gal or NeuAcα2,6GalNAc; Figure 4B ).
Structural analysis of EPO SKOV3 desialylated N-glycans
The N-linked oligosaccharides of purified EPO from SKOV3 cells were released with PNGase F, desialylated by mild acid hydrolysis, and were analyzed by HPAEC-PAD ( Figure 1D) . A large peak corresponding to NeuAc was observed in EPO SKOV3 ( Figure 1D ), with an area of 69% in relation to the total area of the peaks considered from 14 to 30 min of retention time, suggesting that sialic acid is covering a large number of terminal glycan structures. Several peaks eluted at retention times between 16 and 30 min ( Figure 1D ) in the region of the complex-type glycan standards ( Figure 1B ). In comparison with the elution times of the high-mannose-type standards ( Figure 1A) , it was observed that these structures were not present in EPO SKOV3 . Late eluting peaks between 36 and 40 min probably consisted of phosphorylated structures since after incubation with alkaline phosphatase they migrated at earlier retention times in the HPAEC-PAD (data not shown).
The native sialylated glycans of EPO SKOV3 and of control EPO from CHO cells eluted in the same region of the chromatogram. Since control EPO contains NeuAc in the α2,3-linkage (Sasaki et al. 1987) , these results further supported the presence of NeuAc in the α2,3-linkage in EPO SKOV3 .
The total desialylated N-glycan pool released from EPO SKOV3 was also analyzed by MALDI/TOF-MS ( Figure 2B ). Furthermore, individual fractions w-z from the HPAEC-PAD profile ( Figure 1C) were also analyzed by MALDI/TOF-MS. The results of the observed m/z signals and proposed compositions are shown in Table II . As control, the N-glycans of SKOV3 cells transfected with an empty pCDNA3.1/lacZ-V5 vector, which is of the same type as the pCR/EPO vector, and selected with 2 mg/mL of G418 were also analyzed to find out if the transfection/selection process would lead to the expression of different glycan structures. The HPAEC-PAD profiles were similar, which showed that the transfection and the selection procedures did not cause changes in the N-glycan profiles (data not shown).
High-mannose-type structures were not detected ( Figure 2B ), thus corroborating the results obtained by HPAEC-PAD. Signals at m/z 1809.7, 2174.8, and 2539.9 corresponded to di-, tri-, and tetraantennary complex-type structures, all with proximal fucose ( Figure 2B , Table II ). The signal m/z 2905.1 could correspond to a tetraantennary complex-type structure with proximal Fuc and one LacNAc repeat. In addition, signals at m/z 1850.7, 2011.7, 2377.9, and 2743.0 could correspond to the truncated complex-type structures lacking Gal, already described in the section Structural Figure 1C ).
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analysis of SKOV3 desialylated N-glycans. However, other structures are also compatible with the m/z peaks detected.
Owing to the high complexity of the profile, fractions w-z ( Figure 1D ) that contained the major N-glycan components were further analyzed by monosaccharide compositional analysis (Table III) and by MALDI/TOF-MS ( Figure 5) . The results showed the presence of significant amounts of GalNAc in fractions from w to z (Table III) , which indicated the presence of the LacdiNAc motif that was not detected in the EPO BRP N-glycans (Table III) . Furthermore, for the total 
N-glycans from SKOV3 cells, only trace amounts of GalNAc was observed (data not shown).
The mass spectrum of fraction w showed a major signal at m/z 2580.9, which was in agreement with a tetraantennary complex-type glycan with proximal Fuc containing one LacdiNAc motif. The triantennary structure with proximal Fuc and bisecting GlcNAc also compatible with m/z 2580.9 could be excluded since it would elute later than peaks B + C (triantennary, Figure 1 , second panel), and fraction w elutes earlier (20-22 min) than peaks B + C (21.5-23 min). In fact, the addition of one bisecting GlcNAc to an agalactodiantennary structure obtained from IgG leads to a 3.8 min increase in retention time in HPAEC-PAD using the same gradient (data not shown). Additional minor components at m/z 2012. 7, 2053.7, 2174.7, and 2215.7 were also detected and were compatible with complex-type triantennary − Gal, triantennary + one LacdiNAc − Gal, triantennary, and triantennary + one LacdiNAc structures, respectively, all with proximal Fuc.
The major signal at m/z 2377.8 observed for fraction x probably corresponded to a truncated tetraantennary complextype structure with proximal Fuc, minus one Gal. The triantennary structure with bisecting GlcNAc could be excluded since peak x had the same retention time as the triantennary 2,6-branched standard ( peak C, Figure 1 , second panel), whereas the triantennary structure with bisecting GlcNAc would elute later. Additional minor components at m/z 2174.7, 2215.8, 2580.9, and 2784.0 are compatible with complex-type triantennary, triantennary + one LacdiNAc, tetraantennary + one LacdiNAc, and tetraantennary + two LacdiNAc − three Gal structures, respectively, all with proximal Fuc.
In fraction y, the predominant structure was of the tetraantennary type with proximal Fuc (m/z 2539.9). Additional minor peaks at m/z 2174.7, 2215.8, 2377.8, 2418.9, and 2580.9 were also detected and were compatible with the structures discussed before.
The major peak at m/z 2742.9 in fraction z indicated the presence of a truncated tetraantennary complex-type glycan with one LacNAc repeat − one Gal and with proximal Fuc. The tetraantennary structure with bisecting GlcNAc was excluded also based on the retention time by HPAEC-PAD. Additional minor peaks at m/z 2377.8, 2539.9, and 2580.9 were also detected and were compatible with the structures presented before.
In summary, EPO SKOV3 contained complex-type structures, predominantly core-fucosylated tetraantennary structures which partially lacked galactose, and the LacdiNAc motif.
Discussion
In the present study, we have characterized in detail the N-glycans from the ovarian cancer cell line SKOV3 and from the recombinant human EPO secreted by these cells. The results showed that SKOV3 cells contained high-mannose type and complex partially agalactosylated glycans, whereas the secreted glycoprotein contained predominantly corefucosylated tetraantennary structures partially agalactosylated, and partially with the LacdiNAc motif. The LacdiNAc motif has also been found in endogenous glycoproteins from cellular extracts and supernatants.
The present results concerning the presence of high-mannose-type glycans found in SKOV3 cells are in The amount in pmol and percentage of each monosaccharide structure obtained is represented.
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agreement with our previous work, in which the corresponding glycoproteins were detected with the lectin ConA, which binds α-mannosyl branched glycans containing predominantly from the high-mannose type (Escrevente et al. 2006) . Studies from other groups also showed the presence of high-mannose-type glycans in the CA125 marker from the OVCAR-3 ovarian carcinoma cell line (Kui Wong et al. 2003) . More recently, a new monoclonal antibody, TM10, has been developed that recognizes high-mannose structures in glycoproteins from a vast range of human cancer cell lines, including SKOV3 and two other ovarian cancer cell lines, as well as melanoma, prostate, and, to a lesser extent, breast cancer cell lines (Newsom-Davis et al. 2009 ). In prostate epithelial cell lines, high-mannose-type glycans have also been associated with glycoproteins from transformed cells but not from the corresponding wild-type cells nor from the secreted glycoproteins. In the same work, these authors found a downregulation of high-mannose-type structures in the sera of patients but an increase in the Man 5 GlcNAc 2 levels (de Leoz et al. 2008) .
In the present paper, the total N-glycan fractions from SKOV3 cells were analyzed, but they probably largely represent structures from plasma membrane glycoproteins. Supporting this was the recent observation in five thyroid cancer cell lines that 47% of the cellular glycoproteins are associated with the plasma membrane, followed by glycoproteins from the lysosomes (34%), and a lower percentage were derived from the endoplasmic reticulum (16%) and the Golgi and other localizations (4%) (Arcinas et al. 2009 ). Therefore, our results support this recent hypothesis that high-mannose-type glycans from the cell surface may constitute potential biomarkers of tumor cells. This should be further investigated in human tissues. The high-mannose-type glycans might be recognized by lectins from the immune system, for example, the lectin DC-SIGN which is known to recognize high-mannose glycans (Mitchell et al. 2001) , as previously suggested for the high-mannose-containing glycoforms of the ovarian cancer marker, the mucin CA125 (Kui Wong et al. 2003) , which could have immunosuppressive effects.
Regarding recombinant EPO secreted by the SKOV3 cell line, core-fucosylated N-linked glycans bearing the LacdiNAc motif were detected. This structure was also found in the N-glycans of endogenous cellular and supernatant glycoproteins. This structure has been found in the N-glycans of tumor-associated glycoproteins, such as secreted ribonuclease I from pancreatic tumor cells (Peracaula et al. 2003 ) and secreted tissue plasminogen activator from Bowes melanoma cells (Chan et al. 1991) . Glycodelin that is augmented in several gynecological tumors (Horowitz et al. 2001 ) also bears the LacdiNAc structure when isolated from the amniotic fluid (Dell et al. 1995) . This structure has also been found in several other glycoproteins of different species (Manzella et al. 1996; Nimtz et al. 2004 ). In parasitic helminthes, it has been proposed to modulate the immune system of the host (van Die and Cummings 2010) .The N-glycans from EPO partially lacked Gal, which could be due either to incomplete processing or to the presence of glycosidases in cell supernatant.
Our results showed a comparably larger amount of sialic acid associated with the EPO SKOV3 N-glycans than that found in total N-glycans, which could be expected due to the absence of high-mannose glycans in EPO SKOV3 .
The N-glycans of EPO SKOV3 resemble the glycan structures of EPO produced from CHO and baby hamster kidney cells, in that they all contain, predominantly, core-fucosylated tetraantennary complex-type structures, with lower amounts of triand diantennary structures and a high percentage of LacNAc repeats (Sasaki et al. 1987; Takeuchi et al. 1988; Takeuchi and Kobata 1991; Nimtz et al. 1993; Brito et al. 2008) . Moreover, terminal NeuAc was in the α2,3-linkage similar to EPO from those cells (Sasaki et al. 1987; Takeuchi et al. 1988; Nimtz et al. 1993) . Thus, from a biotechnological point of view, the SKOV3 cell line even though producing low amounts of the recombinant protein could be envisaged as a possible source to produce EPO with the specific terminal glycosylation motif LacdiNAc.
In conclusion, we have found that high-mannose glycans were abundant in the ovarian carcinoma SKOV3 cell line but they were not present in secreted recombinant EPO. Furthermore, the less common LacdiNAc motif has been found in endogenous glycoproteins as well as in EPO. The results obtained in the present work opened new perspectives to further explore the significance of cellular high-mannose glycans and the LacdiNAc motif as possible markers of ovarian cancer.
Material and methods
Cell culture
The SKOV3 ovarian carcinoma cell line was cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO), supplemented with 10% (v/v) fetal calf serum, 100 U/mL of penicillin, and 0.1 mg/mL of streptomycin (Invitrogen, Paisley, UK). Cells were grown in a humidified incubator at 37°C in a 5% CO 2 atmosphere.
Production and purification of EPO SKOV3 SKOV3 cells, at 70% confluence were transfected with the plasmid vector pCR3/EPO that encodes human EPO and pCDNA3.1/lacZ-V5 using Lipofectamine Plus reagent (Invitrogen), according to the manufacturer's protocol. Stable SKOV3/EPO cells were obtained by selection with 2 mg/mL of geneticin sulfate (G418; Invitrogen). In a 96-well plate, dilutions from 1.12 × 10 5 to 11 cells per well were done for the selection of higher producing clones. The selected clone was cultured in several T175 cell culture flasks. Successive productions of EPO for 48 h in confluent monolayers of cells in serum-depleted medium were collected and stored at −80°C after a 500 × g centrifugation to remove dead cells and cell debris. The total supernatants were 20-fold concentrated in an Amicon ultrafiltration system with 10 kDa cut-off membrane. Purification of EPO SKOV3 was done by immunoaffinity chromatography using the monoclonal antihuman EPO antibody (Brito et al. 2008) coupled to CNBr-activated Sepharose 4B (Pharmacia, GE Healthcare, Uppsala, Sweden). The sample was applied to the affinity column equilibrated with phosphate-buffered saline (PBS) containing 0.02% (w/v) sodium azide. EPO was eluted with 0.1 M glycine, pH 2.5. Detection of protein was carried out at A = 280 nm. The EPO-containing fractions were neutralized with a 12.5% solution of NH 4 OH.
Quantification of the EPO levels produced by SKOV3 cells was performed in duplicate by western blot analysis, by interpolation of the signal obtained in a calibration curve of peak area vs. a control EPO (biological reference preparation) mass (10-40 ng) with R 2 ≥ 0.97. The peak area was determined using ImageJ 1.37 gel analysis software (National Institutes of Health).
Glycoprotein deglycosylation and analysis SKOV3 cell extracts were done using RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% sodium dodecylsulfate, 1% sodium deoxycholate, 1% Triton X-100, 1% protease N-Glycosylation of SKOV3 cells and EPO inhibitor cocktail Complete (Roche, Basel, Switzerland)) and analyzed after 10,000 × g centrifugation for 10 min.
Samples for deglycosylation with PNGase F and Endo H (Roche) were boiled in the presence of 0.2% (w/v) sodium dodecyl sulfate and 0.1% (v/v) β-mercaptoethanol. After cooling down, 0.4% (w/v) Nonidet P-40 was added followed by 1 U of PNGase F in 50 mM sodium phosphate, 10 mM ethylenediaminetetraacetic acid (EDTA), pH 7.5, or 2.5 mU of Endo H was added in 50 mM sodium citrate, pH 5.5. Samples for hydrolysis of NeuAc were boiled in the presence of 0.5% (w/v) sodium dodecyl sulfate and 0.1% (v/v) β-mercaptoethanol and allowed to cool down. Hydrolysis was carried out by the addition of 15 mU of neuraminidase from V. cholerae (Roche) in 50 mM sodium acetate, 4 mM CaCl 2 , pH 5.5, or 9 U of neuraminidase from S. pneumoniae (Prozyme, Glyco, Hayward, CA) in the buffer supplied. Complete protease inhibitors cocktail tablet (Roche) at 0.02% was added to all samples. The incubations were performed at 37°C, overnight, or for 1 h for the neuraminidase from S. pneumoniae.
Samples were denatured by boiling in sodium dodecyl sulfate polyacrylamide gel electrophoresis sample buffer, and proteins were separated in 12% acrylamide gel by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinyledene difluoride membranes. Membranes were blocked in 5% (w/v) nonfat dry milk (Nestle) in PBS with 0.1% (w/v) Tween-20. Primary antibody used was polyclonal rabbit antihuman EPO (Research and Development) at 1:3000 dilution. Secondary horseradish peroxides-conjugated polyclonal antirabbit IgG antibody (Amersham, GE Healthcare, Amersham, UK) was used at 1:3000 dilution. Chemiluminescent detection was by the Immobilon Western method (Millipore, Billerica, MA).
Glycoproteins were stained with lectins after transfer to the polyvinyledene difluoride membrane. Detection was modified from that described before (Escrevente et al. 2006 ) to increase sensitivity. SNA, MAL (Galab, Geesthacht, Germany), and WFA (Vector Labs., Burlingame, CA) were biotinylated. Briefly, the glycoprotein was fixed on the polyvinyledene difluoride membrane by incubation with 25% 2-propanol and 10% acetic acid for 5 min. For SNA and MAL, the membrane was blocked for 1 h with tris-buffered saline (TBS) containing 2% bovine serum albumin (BSA) and 0.1% Tween-20, or 5% BSA and 0.15% Tween-20 for WFA. Then, incubations with 0.5, 5, and 10 µg/mL of SNA, MAL (overnight), and WFA (2 h), respectively, were done in TBS containing 0.1% Tween-20, followed by 0.02 µg/mL of streptavidin/peroxidase (Sigma) in blocking solution. Development was done by the Immobilon Western method (Millipore).
Total N-glycan isolation from SKOV3 cells Approximately 4.2 × 10 7 SKOV3 cells were homogenized in 2% (v/v) Nonidet P-40 and 0.1% (v/v) benzonase (Sigma) in PBS at pH 7.2. After 30 min incubation, total proteins were precipitated for 2 h at −20°C with 4 volumes of ice cold 100% ethanol and dried in a Speed Vac concentrator (Savant Instruments Inc., Minneapolis/St. Paul, MN). The resulting pellet was incubated for 90 min in 6 M urea, 1 mM dithioerythritol, 0.3 M Tris-HCl, pH 8.3, diluted with buffer and incubated overnight with 70 μg of trypsin (Merk, Darmstadt, Germany) and 0.02% (w/v) sodium azide. Subsequent trypsin inactivation was accomplished by the addition of 0.02% complete protease inhibitor cocktail during 1 h, followed by 10 min incubation at 90°C. Next, the sample solution was subjected to buffer exchange using a 5 kDa Vivaspin concentrator (Sartorius, Aubagne, France) to PNGase F buffer (10 mM NaH 2 PO 4 , 5 mM ethylenediaminetetraacetic acid, pH 7.5). All incubations were performed at room temperature unless otherwise noted.
The N-glycan release from total glycopeptides of SKOV3 cells was performed by incubation in the presence of PNGase F. The reaction was carried out overnight at 37°C with the addition of 50 U of the enzyme in PNGase F buffer. The released N-glycans were separated from the glycoproteins by precipitation with 2.4 volumes of ice cold 100% ethanol for 2 h at −20°C. After centrifugation at 10,000 × g, for 10 min at 4°C, the N-glycans in suspension were removed and two additional washes of the glycoprotein pellet were made with ice-cold 50% ethanol. The supernatants containing N-glycans were pooled and were dried in a Speed Vac concentrator.
N-glycans from purified EPO SKOV3 were released with 20 U of PNGase F, following the procedure described in this section. Complete de-N-glycosylation was monitored by the specific mobility shift of the EPO SKOV3 protein in sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Analysis of desialylated N-glycans by HPAEC-PAD
The glycans samples were desalted using 100 mg of Hypercarb cartridges (Thermo) washed previously with 80% (v/v) acetonitrile (ACN) in 0.1% trifluoroacetic acid (TFA) and three times with water. The N-glycans solubilized in water were then loaded onto the column, followed by three washes with water. The N-glycans from SKOV3 cells were eluted with 40% ACN in 0.1% TFA, and 25% ACN in 0.1% TFA was used to elute EPO SKOV3 N-glycans. The eluted glycans were neutralized with 2.5% (v/v) NH 4 OH and were dried in a Speed Vac concentrator.
The desialylated SKOV3 and EPO SKOV3 N-glycans were prepared by incubation with 5 mM H 2 SO 4 , for 90 min at 80°C
. Hydrolyzed N-glycans were neutralized with 50 mM NaOH and dried in a Speed Vac concentrator.
The analysis of N-glycan structures through HPAEC-PAD was performed using an ICS-3000 ion chromatography system of Dionex Corporation (Sunnyvale, CA), consisting of an AS autosampler, a DC detector/chromatography module, and a DP dual pump. Samples of 20 μL were injected into an equilibrated CarboPac PA200 column equipped with a guard column (3 × 50 mm, Dionex). Released desialylated N-glycans were eluted by using a concentration gradient of 0.1 M sodium hydroxide (solvent A) and 0.1 M sodium hydroxide/ 0.6 M sodium acetate (solvent B), at a flow rate of 0.4 mL/ min. The gradient consisted of a 2 min isocratic run at 100% solvent A, followed by increasing solvent B concentration (9 min to 0.8%, 11 min to 4.5%, 14 min to 18%, 9 min to 30%, 2 min to 100%). The column temperature was constant at 30°C
. The electrochemical detection of the oligosaccharides was performed by application of the detection potentials and durations as recommended by the manufacturer.
Glycan standards from EPO were obtained and characterized as described before (Brito et al. 2008) . Glycan standards from bovine ribonuclease B and from IgG were purchased from TheraProteins and Europa Bioproducts, respectively.
For subsequent MALDI/TOF-MS analysis of individual fractions from the HPAEC-PAD analysis were collected after online desalting using a carbohydrate membrane desalter device (CMD-I, Dionex). Glycan fractions were dried in a Speed Vac concentrator for further analysis.
Analysis of N-glycans by MALDI/TOF-MS Glycans were analyzed with Bruker ULTRAFLEX time-of-flight (TOF/TOF) instrument in the linear positive ion mode. Native desialylated oligosaccharides were analyzed using a matrix of 2,5-dihydroxybenzoic acid as a UV-absorbing material. Samples of 1 μL at an approximate concentration of 1-10 pmol/μL were mixed with equal amounts of the respective matrix and sodium salt. This mixture was spotted onto a stainless steal target and dried at room temperature before analysis. Structures were tentatively assigned to various N-glycans based on their observed masses compared with the calculated masses of known N-glycans. Mass spectrum data were analyzed with the Bruker DataAnalysis for TOF 1.5j program (Bruker Daltonics GmbH) and were smoothed using the Savitzky Golay algorithm in all spectra. Further annotation of N-glycans and database searches were also performed using the Glyco-Peakfinder platform (Maass et al. 2007 ).
